d07f6568-24ba-4c2e-9937-b70b71a2e875Q1 — 1st Quarter - ReportENV — Environment/SuperfundGeneral monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables. General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
FOR — Foreign RelationsGeneral review and monitoring of U.S. diplomatic relations.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
CSP — Consumer Issues/Safety/ProductsGeneral review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
CPT — Copyright/Patent/TrademarkGeneral monitoring of issues and administrative action related to intellectual property protection.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
HCR — Health IssuesGeneral monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA); S.3122 - Better FDA Act of 2025 S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments. General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of coverage for medically necessary services in Medicare and Medicare Advantage; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994; General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter. Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of
MMM — Medicare/MedicaidGeneral monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1; General monitoring of Medicare/MA coverage of dental services; and General review of legislation and rulemaking impacting dual eligible enrollees.
Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
TAX — Taxation/Internal Revenue CodeGeneral monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA; General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
Government entities lobbied: HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); SENATE; Treasury, Dept of
TRD — Trade (domestic/foreign)Monitor and review of issues related to the Section 301 tariffs; Monitor and review of issues related to the Section 232 tariffs; Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act; General monitoring and review of Executive Order 14257 and impacts on OTC products; General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns; General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and General review and monitoring of global supply chain concerns
Government entities lobbied: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS)
FOO — Food Industry (safety, labeling, etc.)General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
FAM — Family issues/Abortion/AdoptionGeneral review of legislative and administration action related to pediatric over-the-counter medication concerns.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
PHA — PharmacyGeneral review and monitoring of processes impacting over-the-counter switches.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TOB — TobaccoGeneral review and monitoring on efforts aimed at preventing youth consumption of tobacco products; General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MAN — ManufacturingGeneral issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products; General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.